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Hallmarks of Alzheimer’s disease (AD) pathology include acetylcholine (ACh) deficiency
and plaque deposition. Emerging studies suggest that acetylcholinesterase (AChE) may
interact with amyloid β (Aβ) to promote aggregation of insoluble Aβ plaques in brains of
patients. Current therapeutic options available for AD patients, such as AChE inhibitors,
provide only symptomatic relief. In this study, we screened four natural compounds
believed to harbor cognitive benefits—curcumin, piperine, bacoside A, and chebulinic
acid. In the first section, preliminary screening through computational molecular docking
simulations gauged the suitability of the compounds as novel AChE inhibitors. From here,
only compounds that met the in silico selection criteria were selected for the second
section through in vitro investigations, including AChE enzyme inhibition assay, 3-(4,5-
dimenthylthiazol-2-yl)-2,5-dimethyltetrazolium bromide (MTT) assay, Thioflavin T (ThT)
assay, and biochemical analysis via a neuronal cell line model. Of the four compounds
screened, only curcumin (−9.6 kcal/mol) and piperine (−10.5 kcal/mol) showed
favorable binding affinities and interactions towards AChE and were hence selected.
In vitro AChE inhibition demonstrated that combination of curcumin and piperine showed
greater AChE inhibition with an IC50 of 62.81 ± 0.01 µg/ml as compared to individual
compounds, i.e., IC50 of curcumin at 134.5 ± 0.06 µg/ml and IC50 of piperine at
76.6 ± 0.08 µg/ml. In the SH-SY5Y cell model, this combination preserved cell
viability up to 85%, indicating that the compounds protect against Aβ-induced neuronal
damage (p < 0.01). Interestingly, our results also showed that curcumin and piperine
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achieved a synergistic effect at 35 µM with an synergism quotient (SQ) value of
1.824. Synergistic behavior indicates that the combination of these two compounds
at lower concentrations may provide a better outcome than singularly used for Aβ
proteins. Combined curcumin and piperine managed to inhibit aggregation (reduced
ThT intensity at 0.432 a.u.; p < 0.01) as well as disaggregation (reduced ThT intensity at
0.532 a.u.; p < 0.01) of fibrillar Aβ42. Furthermore, combined curcumin and piperine
reversed the Aβ-induced up-regulation of neuronal oxidative stress ( p < 0.01). In
conclusion, curcumin and piperine demonstrated promising neuroprotective effects,
whereas bacoside A and chebulinic acid may not be suitable lead compounds. These
results are hoped to advance the field of natural products research as potentially
therapeutic and curative AD agents.
Keywords: Alzheimer’s disease, amyloid beta, acetylcholinesterase, curcumin, piperine
INTRODUCTION
Alzheimer’s disease (AD) is the most common form of
dementia, accounting for up to 60%–70% of cases worldwide.
This neurodegenerative disorder mostly affects individuals aged
60 and above, with a projected prevalence of 100 million
patients worldwide by the year 2050 (Dua et al., 2017).
Despite the alarming figures, current therapeutic approaches
available are merely symptomatic treatments that slow down
cognitive decline with modest results; none of them are able
to stop, prevent, or cure the disease (Galimberti and Scarpini,
2016). Three out of the four drugs available in the market,
i.e., donepezil, galantamine, and rivastigmine, belong to the
class of acetylcholinesterase (AChE) inhibitors. Based on their
mechanism of action, targeting AChE pharmacologically for AD
is reported to increase acetylcholine (ACh) concentration within
the synapse, modulated through the binding of an inhibitor
molecule to the catalytic action site (CAS) of the enzyme. Thus,
with the decrease in ACh breakdown, it can compensate for
the loss of functional neurons in early to mid-stages of the
disease (Ali et al., 2015). As neurotransmission is reduced in
the brains of AD patients due to the presence of neurotoxic
amyloid plaques and fibrillary tangles, the increased levels of
ACh are able to prolong cholinergic neurotransmissions and
address cognitive symptoms such as learning and memory
impairments (Kandimalla and Reddy, 2017). Unfortunately, as
disease advances to the later stage with lesser intact neurons
remaining, the drug action is likely insufficient to counteract
the neurotransmission deficits. At this point, the downward
spiral of cognitive function can no longer be kept in control
(Mitchell et al., 2017).
Amyloid precursor protein (APP) discovered in healthy
human brains is deemed to have a normal functional role.
However, amyloid β (Aβ), a 39- to 43-amino-acid residue peptide
produced from the proteolytic cleavage of APP, is believed to
be the key fragment in propagating AD pathology (Castello and
Soriano, 2014). The progressive deposition of Aβ aggregates
is extensively credited to be fundamental to the primary
development of neurodegenerative pathology through triggering
a cascade of events such as neurotoxicity, oxidative damage,
and inflammation that collectively contribute towards the
progression of AD (Penke et al., 2017; Limbocker et al., 2018). In
addition to plaque deposition, Aβ fibrils or soluble Aβ oligomers
are intrinsically toxic to the cells by triggering the formation
of reactive oxygen species (ROS), consequently attacking lipid
membranes, which further facilitates lipid peroxidation while
lowering the levels of first-line defense enzymes such as catalase
and glutathione (Cheignon et al., 2018).
Therefore, emerging evidence of an area responsible for Aβ
plaque aggregation activities within the AChE is promising,
creating prospects of new treatment targets that potentially alter
the course of disease progression, on top of managing the
associated signs and symptoms. Identified as peripheral anionic
site (PAS), an inhibitor compound at this site is expected to
suppress plaque formation and deposition, hence interrupting
with the downstream neuropathological cascade (Kracˇmarová
et al., 2015). From here, the improved drug compound is
proposed to interact simultaneously with both PAS and CAS of
AChE. This offers an advantage compared to the drugs available
at present; for example, galantamine binds to only CAS within
the AChE and donepezil binds to either site, although it does so
respectively, rather than both sites at once (Chierrito et al., 2017);
hence, it is only marketed as a CAS inhibitor (Mehta et al., 2012).
Furthermore, side effects such as nausea, vomiting, diarrhea, and
dizziness have been commonly reported, which cause patients to
have reduced adherence to their prescribed medications (Hansen
et al., 2008). Thus, the search for a novel dual-site binding to
AChE inhibitor is paramount to stop AD progression.
Of particular interest to researchers is in the area of natural
products, in which the intrinsic bioactive compounds are known
to possess various beneficial biological effects (Bui and Nguyen,
2017). This study investigates four natural compounds that are
traditionally believed to offer cognitive benefits. These culinary
herbs and medicinal remedies that are commonly used in
Asia are curcumin from Curcuma longa, piperine from Piper
nigrum, bacoside A from Bacopa monniera, and chebulinic acid
from Terminalia chebula. The specific physiological benefits
derived from these compounds are comprehensive, including
epidemiological reports from improved cognitive functions in
those who incorporate curcumin into their normal diet as
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opposed to those who do not (Ng et al., 2006). In addition,
piperine attenuates memory impairment and neurodegeneration
in cholinergic deficient rats (Chonpathompikunlert et al.,
2010) while bacoside A is an iron chelator, where brain iron
dyshomeostasis is strongly associated with AD pathology (Lane
et al., 2018). Chebulinic acid, as well as the aforementioned
three compounds exhibit anti-inflammatory and antioxidant
effects, which have been reported to inhibit Aβ plaque
formation and subsequently prevent Aβ-induced neurotoxicity
(Afshari et al., 2016).
This study is divided into two parts: in silico screening
followed by in vitro validation and further testing. Conducted
through computational molecular docking simulations, this
preliminary screening step gauges the suitability of the four
compounds as novel AChE inhibitors. It investigates the binding
affinities between the natural compounds and AChE receptor.
Interactions of each ligand with key amino acids of receptor
will also be studied to determine the abilities of the natural
compounds in interacting with both CAS and PAS sites of AChE.
From here, only the compounds that meet the in silico selection
criteria would be selected for subsequent in vitro investigations
via a neuronal cell line model, including AChE enzyme inhibition
assay and reversal of oxidative damages. At the end of this study,
ideal lead compounds, either individually or in combination, will
be recommended for their neuroprotective effects. The results
of this study is hoped to advance the field of natural products
research as potential therapeutic and curative AD agents.
RESEARCH DESIGN
A summary of the research design is shown in Figure 1. In
brief, four compounds were screened for their binding profiles
with AChE receptor. The compounds that fulfilled the criteria
of good binding affinity and key interactions with receptor
were shortlisted for subsequent in vitro AChE inhibition activity
where the compounds, individual and combined, were evaluated
through maximal inhibition activity (IC50). We further evaluated
the effects of selected compounds against Aβ-induced damages
using the SH-SY5Y cell line. Details for each part of the
methodology are further discussed in the following sections.
In Silico AChE Screening
Preparation of Receptor and Ligand Files
The structure of AChE (PDB ID: 4EY6) with a resolution
of 2.3983 Å was downloaded from Protein Data Bank in
RCSB PDB format. Using Discovery Studio 2017 R2 (Dassault
Systèmes BIOVIA, San Diego, CA, USA), the target structure was
optimized by removing water molecules and all other ligands in
the complex as they may affect the binding conformation and
interactions. Among the ligands co-crystallized was galantamine,
which is a type of FDA-approved AChE inhibitor drug. One of
the identical chain in the homodimer structure was also deleted
to minimize docking run time. Hydrogen atoms were then added
and converted to pdbqt files.
The structures of ligands, curcumin (PubChem CID: 969516),
piperine (PubChem CID: 638024), bacoside A (PubChem CID:
92033183), and chebulinic acid (PubChem CID: 250396) were
downloaded from PubChem in SDF format. 3D format was
chosen for curcumin and piperine. As bacoside A and chebulinic
acid were only available in 2D formats, their 3D form was
generated using OpenBabel software. The number of atoms
was checked to ensure that no errors had occurred. All four
ligands were converted to pdb format using Discovery Studio
2017 followed by conversion to pdbqt format using AutoDock
Tools 1.5.6. Hydrogen atoms were added to the structures as well.
Through root detection and setting of rotatable bonds, ligands
were designated as flexible during the docking process. This is
in line with the induced fit theory that generates a diverse set
of ligand poses within the search space of receptor binding site
(Clark et al., 2016).
Determination of Search Space on AChE
Receptor
The docking search site, where ligands would explore possible
binding interactions with AChE, was determined using
AutoDock Tools 1.5.6 (Morris et al., 2009). This search
space (also known as AutoGrid) was positioned to encompass
both CAS and PAS within the AChE gorge. The center for the
3D cuboidal AutoGrid box was set at (x: −12.3199, y: −42.071,
z: 28.832) while the number of points in dimension for AutoGrid
box was set at (x: 24, y: 20, z: 20). The relative position of
AutoGrid in AChE is shown in Figure 2 below.
Molecular Docking Using AutoDock Vina
Command prompt was used to perform the molecular docking
runs. The command line for docking specified the locations
of AutoDock Vina software, target receptor and ligand pdbqt
files, configuration text file, as well as the desired location of
output data. Each ligand-receptor pair under a specific AutoGrid
box was subjected to 100 runs of docking, a sufficient number
based on a docking system reviewed by Oferkin et al. (2015).
In total, 400 runs were conducted for AChE target receptor
at the end of this study. The resulting AutoDock Vina output
files in pdbqt format recorded the poses generated while the
text data listed binding energies for the corresponding poses
(Trott and Olson, 2010).
Analysis of Molecular Docking Data
The two data obtained from molecular docking were the
binding affinity in terms of binding energy (kcal/mol) and the
visualization of binding conformation for each docking mode
using PyMOL.
Binding Diagram Analysis
From the poses generated, conformation of ligands with the least
binding energy was extracted using PyMOL. The binding of each
ligand to AChE target receptor was visualized subsequently.
2D Interaction Diagram
2D interaction diagram for the best pose of each ligand was
captured using Discovery Studio 2017. The list of interactions
was recorded and the bond diagrams between ligands
were compared.
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FIGURE 1 | Summary of computational and experimental approach conducted in this study.
FIGURE 2 | Relative position of AutoGrid box in acetylcholinesterase (AChE)
encompassing both catalytic action site (CAS) and peripheral anionic site
(PAS) docking sites.
Molecular Surface Analysis
The best pose of each ligand was subjected to hydrogen bonding
and hydrophobicity plot analyses using Discovery Studio 2017.
In vitro AChE Screening
Preparation of Compounds and Standard Drug
Following the findings from the molecular docking study,
selected compounds and donepezil were dissolved in absolute
dimethyl sulfoxide (DMSO) to make a 1,000µg/ml stock solution
and further diluted to desired concentrations.
Determination of AChE Inhibitory Activity
This assay was carried out following the protocol in the AChE
assay kit (ABCAM, UK). This kit detects AChE inhibitory activity
using DTNB to quantify the Thiocholine produced from the
breakdown of Acetylthiocholine enabled by AChE. DTNB reacts
with the sulfhydryl group (–SH) in Thiocholine and acts as a
colored reagent (yellow) for colorimetry analysis. Absorbance
readings were measured using a microplate reader at OD 410 nm.
This assay can detect up to a minimum of 0.1 mU AChE in a
100-µL assay volume (1 mU/ml), which served as a reliable and
sensitive test for this study.
Statistical Analysis
The absorbance readings were expressed as mean values of
the triplicates, and a linear regression model showing the
absorbance values of the standard solutions was plotted.
The R2 value was obtained and evaluated. Next, the IC50
(the concentration required for 50% inhibition) values were
calculated by constructing a non-linear regression graph between
percentage inhibitions of selected compounds vs. concentration,
using Graph Pad Prism software v.8.0.1 (GraphPad Software Inc.,
San Diego, CA, USA).
In vitro Cell Line Screening
Cell Line and Cell Culture
Human neuroblastoma cells (SH-SY5Y) were purchased from
ATCC, USA. The cell lines were maintained in DMEM
(ATCCr 30-2002TM), supplemented with 10% FBS and 5%
penicillin/streptomycin, and incubated in a humidified 5% CO2
37◦C incubator.
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Cell Proliferation Assay
Cell proliferation assay was performed using the
3-(4,5-dimenthylthiazol-2-yl)-2,5-dimethyltetrazolium bromide
(MTT) method. SH-SY5Y cells were seeded at 4 × 105/ml
in 96-well plates. When the cells reached 80% confluency,
curcumin, piperine, and donepezil were added at different
concentration gradients (curcumin: 2.5–100 µM; piperine and
donepezil: 2.5–50 µM), followed by a 24-h incubation. Stock
solution of MTT (Sigma; 5 mg/ml) was added into each well and
incubated at 37◦C in a CO2 incubator for 3 h. MTT medium
was then carefully aspirated from the wells, and the formazan
dye was eluted using DMSO. Absorbance was measured using
SPECTROstar Nano microplate reader (BMG Labtech, Cary,
NC, USA) at a wavelength of 570 nm and formazan product
was measured as an index of cell proliferation. Cell viability
percentage was calculated and expressed relative to the value in
the vehicle-treated control culture. Effective concentration (EC)
of each individual compound was optimized and selected for
further experiments.
Combination Study
The concentration of compounds prepared for testing of the
combinatorial effect was in 2-fold dilutions from the final
concentration. These compounds were added in a ratio of 1:1,
using the checkerboard dilution method (Chang et al., 1995; Su
Wei Poh et al., 2015).
Synergy Quotient Calculation for
Synergism
The synergism quotient (SQ) was calculated by subtracting
baseline values from all treatments and then dividing effects
of combined treatments by the sum of individual treatments.
An SQ greater than 1.0 indicates a synergism for a given
measured response.
Aβ Disaggregation Assay
Aβ Preparation
Synthetic Aβ42 fibril was prepared as described previously with
slight modifications (Tycko, 2018). In brief, the Aβ42 peptide was
dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP, Sigma) at
1 mg/ml and aliquoted in Eppendorf tubes. The HFIP was
allowed to evaporate in the fume hood, and the resulting clear
peptide film was dried under vacuum overnight. The traces of
HFIP were removed under vacuum (Speed Vac; Thermo Fisher
Scientific, Waltham, MA, USA) on the next day and resuspended
in DMSO to a concentration of 5 mM. To form fibrillar
conditions, the peptide was diluted to a final concentration of
100 µM with 10 mM of acid hydrochloric (HCI) solution and
incubated at 4◦C for 24 h.
Thioflavin T (ThT) Fluorescence Assay
To test the inhibition and disaggregation effect of curcumin
and piperine on Aβ fibrils, 25 µM Aβ42 fibril was incubated
with 5 µM Thioflavin T (ThT) solution. Fluorescence intensity
was monitored at an excitation wavelength of 450 nm and an
emission wavelength of 482 nm using a spectrometer.
Biochemical Analysis
Measurement of Malondialdehyde (MDA),
Glutathione, and Catalase
The malondialdehyde (MDA) level was measured using Lipid
Peroxidation Kit (Abcam, UK). In this assay, the MDA in
the sample was allowed to react with Thiobarbituric Acid
(TBA) to generate the MDA-TBA adduct. The MDA-TBA
adduct was quantified colorimetrically at a wavelength of
532 nm. Reduced glutathione (GSH) level was measured using
Glutathione peroxidase (GPx) Assay Kit (Abcam, UK). In this
assay, GPx reduces cumene hydroperoxide while oxidizing GSH
to oxidize glutathione (GSSG). The generated GSSG is reduced
to GSH with consumption of NADPH by glutathione reductase
(GR). The decreased NADPH is proportional to GPx activity,
which the absorbance was measured at 340 nm in this study.
Catalase activity was determined with catalase assay kit (Abcam,
UK). In the assay, catalase first reacts with hydrogen peroxide
(H2O2) to produce water and oxygen, and the unconverted H2O2
reacts with OxiRedTM probe to produce a product, which was
measured colometrically at 570 nm.
Statistical Analysis
All data were expressed as mean ± SEM (standard error of the
mean). Data collected were analyzed using one-way ANOVA
via a statistical software GraphPad Prism version 8.0 (GraphPad
Software Inc., San Diego, CA, USA), where ∗p < 0.05 and
∗∗p ≤ 0.01.
RESULTS
Computational Approach
Analysis of Binding Affinity and Binding Energy
Molecular docking of the four ligands to AChE was carried
out using AutoDock Vina 1.1.2. Following 100 docking runs
for each ligand and data sorting, the results for the best
binding conformation of each ligand to AChE are tabulated
in Table 1. From Table 1, negative binding energies were
recorded for all four ligands, indicating that they were generally
favorable and have a stable binding to AChE receptor.
Based on the binding affinities of the ligands, we postulate
that the binding between piperine to AChE receptor is
the most stable, followed by curcumin, chebulinic acid and
bacoside A.
2D Interaction Diagram Analysis
The 2D interaction diagrams for each docked ligand
within AChE were generated using Discovery Studios 2017
TABLE 1 | Binding energies and interactions observed between the top pose of
each ligand with acetylcholinesterase (AChE) receptor.
Ligand Binding affinity (kcal/mol) Interaction(s) with AChE sites
CAS PAS
Curcumin −9.6 √ √
Piperine −10.5 √ √
Bacoside A −3.2 √
Chebulinic acid −6.7 √
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FIGURE 3 | Binding interactions of ligands to AChE. Amino acids in orange box represent CAS residues, blue box for PAS, while the remaining amino acids are
residues that were involved in stabilizing the binding within the AChE gorge.
FIGURE 4 | Color coding of non-covalent interactions linking
ligand–receptor pairs. The interaction can be categorized into five groups,
namely, hydrogen bonds, electrostatic, hydrophobic, and unfavorable linkage.
(Figures 3, 4). We analyzed and compared the interactions,
which provided valuable information on the docking profiles
of each ligand. Detailed information of each bond formed is
included in Supplementary Table S1.
In this study, the search space of AChE was defined to
encompass two distinct binding sites, CAS and PAS. The CAS
consisted of amino acids SER203, HIS447, and GLU334 whereas
the PAS consisted of amino acids TYR72, ASP74, TYR124,
TRP286, and TYR341. Based on Figure 3, only curcumin
and piperine were able to bind to both CAS and PAS sites
simultaneously. It showed that curcumin bound to SER203 in
the CAS and to TYR124 and TRP286 in the PAS, while piperine
bound to SER203 and HIS447 in the CAS and to TRP286 in
the PAS. Absence of CAS binding was noted in both bacoside A
and chebulinic acid. Additionally, unfavorable binding was seen
between bacoside A and chebulinic acid to AChE, as denoted by
the presence of red lines.
Molecular Surface Analysis
Molecular surface analysis is divided into two
sections—hydrogen bonding and degree of hydrophobicity.
Hydrogen bonding provides further understanding on the
differences in binding affinity while the degree of hydrophobicity
is important in the pharmacokinetic properties of a drug. Both
hydrogen bonding and hydrophobicity interaction diagrams
between ligands and AChE were generated using Discovery
Studios 2017 and demonstrated in Figures 5, 6.
The number of hydrogen bonds can affect the binding affinity
of ligand towards receptor. Based on Supplementary Table
S1, CAS and PAS of AChE consist of mainly hydrogen bond
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FIGURE 5 | Hydrogen bond molecular surface mapped the locations of hydrogen bonds in ligands when bound to AChE. Curcumin and piperine demonstrated a
high number of hydrogen bond donors and hydrogen bond acceptors. Meanwhile, bacoside A showed a higher number of hydrogen bond donors while chebulinic
acid presented with a higher number of hydrogen bond acceptors.
donors. As hydrogen bonding requires a hydrogen bond donor
and an acceptor to form the bond, chebulinic acid should have
the highest binding affinity, whereas bacoside A should have
the lowest binding affinity. From the hydrophobicity results,
it is indicated that bacoside A would have the highest value
of hydrophobicity (log P) while chebulinic acid has the lowest
log P-value.
Based on our computational results, only curcumin and
piperine were selected for subsequent in vitro studies.
Experimental Approach
In vitro AChE Inhibition Assay
A low IC50 value suggests better efficacy and lower potency
of drug required for enzyme inhibition. Out of all the test
compounds studied, combined curcumin and piperine (IC50:
62.81 ± 0.01) exhibited comparable enzymatic inhibitory effect
to donepezil (IC50: 54.79 ± 0.01; Table 2). Likewise, the IC50
values for combined curcumin and piperine were much higher
than the individual curcumin (134.5 ± 0.06) and piperine
(76.6± 0.08).
In vitro Cell Line Screening
Curcumin and Piperine Induced Dose-Dependent Increase
in Cell Proliferation in SH-SY5Y Cells
In our in vitro cell line model, we observed the degeneration
effects of Aβ in cultured SH-SY5Y cells that served as a neuronal
cell model. Our dose–effect curve result showed that curcumin
achieved EC50 at 49.11 µM, piperine at 25.02 µM, and donepezil
at lower concentration, which was at 10.94 µM after 24 h
incubation in SH-SY5Y cells (Figure 7).
Activity of Combined Curcumin and Piperine in the
Combination Treatment
For the combination study, synergistic activity was observed
between 25 and 50 µM of curcumin and 10–25 µM of piperine
(total dose, 35 µM), calculated based on the SQ calculation
(Figure 8). The maximum synergistic activity was observed at
25 µM of curcumin and 10 µM of piperine, with an SQ of 1.824.
In this study, higher concentration of curcumin (25–50 µM)
with piperine (10–25 µM) was shown to induce a synergistic
activity, while an antagonistic activity was observed with
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FIGURE 6 | Degree of hydrophobicity on the molecular surface of ligands when bound to AChE. Curcumin and piperine both have similar sizes of areas with low
hydrophobicity and areas of low hydrophilicity. Meanwhile, bacoside A has a larger area of hydrophobicity while chebulinic acid has a smaller area of hydrophobicity.
TABLE 2 | Percentage of AChE inhibition and IC50 results for selected test compounds.
Test compounds % Inhibition IC50 ± SEM (µg/ml)
25 µg/ml 50 µg/ml 100 µg/ml 250 µg/ml 500 µg/ml
Donepezil 63.66 71.43 90.22 90.30 90.30 54.79 ± 0.01
Curcumin 7.14 18.01 31.68 51.86 71.43 134.5 ± 0.06
Piperine 21.97 48.06 54.27 75.08 80.98 76.6 ± 0.08
Curcumin + Piperine 12.5 20.26 90.37 90.84 91.23 62.81 ± 0.01
lower concentrations of curcumin (2.5–10 µM) and piperine
(2.5–5 µM). This could be because both curcumin and piperine
exert activity at higher concentrations, singularly.
Combined Curcumin and Piperine Against Aβ-Induced
Cytotoxicity
The cells treated with 25 µM of Aβ42 in the absence or
presence of all test compounds and their viabilities were
measured using the MTT assay. In the absence of test compound,
25 µM Aβ42 exhibited a substantial toxic effect, which reduced
cell viability to 20% (Figure 9). However, pre-incubation
of all test compound with Aβ42 (25 µM) presented a
pronounced decrease in cell toxicity, where cell viability was
effectively restored up to 85%, demonstrating a distinct effect
of compound upon Aβ42 cytotoxicity. We also compared the
effect of individual compound and combined compound against
cytotoxicity. The combination of curcumin and piperine at
35 µM significantly preserved cell viability (85%) as compared
to individual compounds (curcumin: 75%, piperine: 65%) at
p< 0.01.
Aβ Disaggregation Assay
Combined Curcumin and Piperine Inhibit and Disaggregate
Fibril Formation
From our findings, ThT analysis demonstrated that in both
cases, all compounds clearly inhibited fibrillation of Aβ42 as
shown in Figure 10A and disaggregated the fibrils as shown
in Figure 10B, as reflected in the lower intensity of the
ThT fluorescence. Interestingly, more pronounced inhibition
(reduced ThT intensity at 0.432 a.u. compared to the Aβ
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FIGURE 7 | Dose–response relationships for curcumin, piperine, and
donepezil used singularly in various concentration gradients from 2.5 µM to
100 µM. Each curve represents the increase in cell viability as a function of
the dose. Effective concentration (EC) was calculated using GraphPad Prism.
FIGURE 8 | Effect of varying concentrations of curcumin and piperine used
in combination in SH-SY5Y cells proliferation after 24 h. Synergism quotient
(SQ) values were calculated to determine if there was any synergistic activity
in the treatment. The results presented are averages of three independent
experiments each done in triplicate and expressed as the mean ± SEM.
∗p < 0.05, ∗∗p < 0.01, one-way ANOVA with Dunnett’s test compared to
combined curcumin and piperine group (CuR: Pip).
group) and disaggregation (reduced ThT intensity at 0.532 a.u.
compared to Aβ group) of Aβ42 fibrillation were observed with
the combined curcumin and piperine.
Biochemical Analysis
Combined Curcumin and Piperine Attenuates Aβ-Induced
Oxidative Damage
As shown in Figure 11, upon pre-incubation of Aβ42 at 25 µM
in cultured SH-SY5Y cells for 24 h, Aβ42 caused a substantial
increase in the level of lipid peroxidation end product: (a) MDA
level (increased 1.6 nM/mg protein in MDA level compared to
untreated group; p < 0.01); (b) with an obvious decrease in the
level of glutathione (reduced 0.081µM/mg protein in glutathione
level compared to untreated group; p < 0.01); and (c) catalase
FIGURE 9 | Effects of amyloid β (Aβ), Donepezil + Aβ, curcumin + Aβ
(CuR + Aβ), piperine + Aβ (Pip + Aβ), and combined curcumin and piperine +
Aβ [(CuR + Pip) + Aβ] in SH-SY5Y cell proliferation after 24 h treatment. The
cell viability percentage was calculated relative to the untreated group and
expressed as the mean ± SEM. ap < 0.05 compared to untreated cells,
bp < 0.01 compared to the Aβ group, cp < 0.01 compared to the
(CuR: Pip) + Aβ group (one-way ANOVA followed by Tukey’s test).
enzyme (reduced 26 µ/g protein in catalase level compared
to untreated group; p < 0.01). For the groups that received
treatment of all compounds singularly including donepezil,
curcumin, and piperine followed by addition of Aβ, results
showed a significant reduction (p < 0.05) in the level of MDA
(total reduction: donepezil + Aβ: 1.2 nM/mg protein, CuR + Aβ:
1.0 nM/mg protein, and Pip + Aβ: 1.1 nM/mg protein compared
to the Aβ group) while significant elevation (p< 0.05) in the level
of antioxidant enzyme, glutathione (total elevation: donepezil +
Aβ: 0.048 µM/mg protein, CuR + Aβ: 0.059 µM/mg protein, and
Pip + Aβ: 0.06 µM/mg protein compared to the Aβ group), and
catalase level (total elevation: donepezil + Aβ: 16 µ/g protein,
CuR + Aβ: 19 µ/g protein, and Pip + Aβ: 17 µ/g protein to the
Aβ group). However, combination of curcumin and piperine at
35 µM exerted greater effects (reduced 1.7 nM/mg protein in
MDA level, increased 0.073 µM/mg protein in glutathione level,
and increased 24 µ/g protein in catalase level compared to the Aβ
group) than compounds used singularly at p< 0.01.
DISCUSSION
With unparalleled bioactive components and structural diversity,
natural products remain the most pivotal source of novel
compounds for therapeutic drugs development (Yuan et al.,
2016). Considering that Asia is home to a plethora of flora and
the wide use of medicinal herbs and culinary spices across the
continent, elucidating the bioactivity of these phytochemicals
would give a better understanding of its mechanism of
action and potential adaptation into pharmaceutical drugs
(Jantan et al., 2015). Molecular docking was conducted on
curcumin, piperine, bacoside A, and chebulinic acid, all of
which are traditionally believed to harbor nootropic benefits
(Chonpathompikunlert et al., 2010; Goozee et al., 2016;
Nemetchek et al., 2017; Uddin et al., 2019). In this study, in silico
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FIGURE 10 | Thioflavin T (ThT) fluorescence assay of SH-SY5Y cells treated with Aβ, Donepezil + Aβ, curcumin + Aβ (CuR + Aβ), piperine + AB (Pip + Aβ), and
combined curcumin and piperine + AB [(CuR + Pip) + Aβ] on (A) inhibition and (B) disaggregation of preformed Aβ fibrils (n = 3, ∗p < 0.05, ∗∗p < 0.01 compared to
the Aβ group, one-way ANOVA followed by Tukey’s test).
FIGURE 11 | Biochemical assay of SH-SY5Y cells treated with Aβ, Donepezil + Aβ, curcumin + Aβ (CuR + Aβ), piperine + Aβ (Pip + Aβ), and combined curcumin
and piperine + Aβ [(CuR + Pip) + Aβ]. (A) Lipid peroxidation assay, (B) glutathione assay, (C) catalase assay. Values were presented as mean ± SD, from three
independent experiments. ∗p < 0.01, compared to untreated group. #p < 0.05, ##p < 0.01, compared to the Aβ group (one-way ANOVA followed by Tukey’s test).
MDA, malondialdehyde; GSH, glutathione; Cat, catalase.
docking was first employed as an efficient and cost-saving
method for the initial filtering of lead candidates in drug
discovery for AD. Through simulations, the binding affinities
and types of interactions of each ligand within the binding
pocket of AChE receptor were identified. Following screening
and selection of compounds, in vitro studies were then carried
out for validation and further testing.
Binding affinity, also termed binding energy, is the energy
released or consumed when a ligand binds to its receptor
(Purich, 2010). If the binding occurs spontaneously and is thus
favorable, the overall energy of the complex would be reduced,
as denoted by a negative score. Conversely, unfavorable binding
consumes energy and is given a penalty of positive score. On
an arbitrary scale, the more negative is the binding energy, the
more stable the ligand-receptor complex is, and vice versa (Du
et al., 2016). As summarized in Table 1, although all ligands
recorded negative energies, curcumin and piperine at −9.6 and
−10.5 kcal/mol were evidently the stronger ligands that bound to
AChE receptor, as compared to bacoside A and chebulinic acid at
−3.2 and−6.7 kcal/mol, respectively. In curcumin and piperine,
the lower binding energies were the results of hydrogen bonds,
electrostatic charges, and hydrophobic interactions, forming a
stable docked complex. As for the small differences noted, it
can be explained through the number of bonds formed between
ligand and receptor. Piperine formed six hydrogen bonds and
five hydrophobic interactions with AChE, whereas curcumin
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only formed four hydrogen bonds and one hydrophobic bond
with AChE, hence the greater affinity in piperine. However, in
bacoside A and chebulinic acid, although similar non-covalent
interactions were observed, the overall affinity towards AChE
receptor was reduced by unfavorable bond(s), indicating
repulsion forces that destabilized the complex. Considering that
in the in vivo state, with AChE inhibitors being in competition
with endogenous ACh substrate for binding to the receptor, we
believe that AChE would preferentially bind to the ligand that
has a more favorable affinity towards it. Hence, it is imperative
that potential AChE inhibitors exhibit greater binding stability
to maximize on its enzymatic inhibition and plaque aggregation
prevention properties.
Binding affinities were also determined by the molecular
size and structure of the ligands (Atkovska et al., 2014). Based
on molecular weights (MW), both bacoside A (768.982 g/mol)
and chebulinic acid (956.68 g/mol) were more than 2-fold
greater compared to curcumin (368.385 g/mol) and piperine
(285.343 g/mol). From the greater number of atoms in the bigger
ligands, it was initially assumed that they were able to form more
interactions that could contribute to greater stabilization with
the receptor. However, in this case, since the CAS binding site
is located at the base of a ∼20-Å-deep and ∼5-Å-narrow gorge
(Cheng et al., 2017), it is believed that the limited space within the
binding cavity was unable to accommodate the larger structures
of bacoside A and chebulinic acid, causing the ligands to adopt
unfavorable conformations, hence the poorer score. Another
postulation for bacoside A and chebulinic acid to have higher
binding energies can be due to their abilities to bind and interact
with either CAS or PAS at a time instead of simultaneously as
seen in the interactions of curcumin and piperine towards AChE.
For reference, known AChE inhibitors such as donepezil and
physostigmine (used in the treatment of myasthenia gravis) with
smaller MW of 379.500 g/mol and 375.352 g/mol, respectively,
have a similar range of MW to curcumin and piperine,
thereby reaffirming our rationale of correlating molecular size to
binding space.
From the identification of SER203, GLU334, and HIS447 as
the key amino acids involved in the hydrolysis of ACh, it
is postulated that access of ACh to the catalytic triad would
be blocked if ligands were bound to any of these residues.
Hence, the potential of enzymatic inhibition in ligands can be
evaluated based on the evidence of SER203, GLU334, and/or
HIS447 interaction(s). As for PAS, contacts with TYR72, ASP74,
TYR124, TRP286, and/or TYR341 can be deemed as successful
inhibition of PAS. From Table 1, only curcumin and piperine
achieved contact with both sites while bacoside A and chebulinic
acid interacted with PAS only.
The orientation adopted by each ligand within the AChE
gorge can be elucidated based on the interaction with amino
acids. As mentioned above, the three CAS amino acids are
buried deep inside the gorge while five amino acids forming
the PAS are located close to the entrance of the gorge (Johnson
et al., 2003). From Figure 3, the successful interactions with
both sites as seen in curcumin and piperine were due to their
linear structures, enabling the molecules to span the length of
the gorge. In contrast, the evidence of only PAS interaction seen
in bacoside A and chebulinic acid indicates that the structures
were not able to penetrate deeply into the CAS. This is especially
evident in bacoside A, where the bulky glycoside group was
unable to cross the bottleneck gorge entrance. Although several
bacoside A and chebulinic acid with higher binding energies
were seen to interact with CAS amino acids, this was achieved
at the expense of adopting conformations that caused further
penalties to the docking affinities (lower-ranked pose results
not shown). Since a potential inhibitor has to be able to
competitively bind with AChE in the presence of ACh (Nair
and Hunter, 2004), only the top pose is relevant and considered
in this study.
In addition, insights into the bottleneck structure at the AChE
gorge entrance have shown that even endogenous ACh substrate
could only cross the narrowest portion when the gate opens
momentarily (Henchman et al., 2002; Cheng et al., 2017). In
light of this transient entry mechanism, we presume that an
inhibitor ligand with dual-site binding capability would be a
more potent and efficacious drug compared to ligands that bind
to either site only, by reasoning that the former would only
need to cross the gate once. This, therefore, underscores the
importance of selecting inhibitor ligands that are both CAS and
PAS binders (Fang et al., 2014) and, at the same time, forms
stable ligand-receptor complex with AChE. Hence, the drug
potential of the four ligands is determined based on binding
energies and evidence of interaction with the key amino acids at
both sites.
In molecular surface studies, it is observed that CAS and PAS
of AChE consist of mainly hydrogen bond donors. Therefore,
it will form a greater number of hydrogen bonds with ligands
rich in hydrogen bond acceptors because both are required
in order to form hydrogen bonding (Brown, 2009). Although
it was postulated that chebulinic acid with greater number of
hydrogen bond acceptors should be able to bind to AChE
with the greatest affinity, it is ranked the third in terms of
binding energy to AChE. The penalty in score imposed by
the presence of unfavorable bonds is most likely attributed to
bulkiness of chebulinic acid structure as mentioned above. This
analysis further validates the reasoning behind our docking
results. The second part of molecular surface interaction studying
hydrophobicity gives a preliminary idea on the penetrance ability
of compounds across the blood-brain barrier. Theoretically,
high hydrophobicity gives higher log P-values that indicate
how effective a ligand can enter the central nervous system
and bind to AChE in the brain. Since bacoside A has the
largest area of hydrophobicity, it can be suggested that it
has the highest log P-value. To confirm this postulation,
however, further analysis such as quantitative structure-activity
relationship (QSAR) has to be conducted to determine the actual
hydrophobicity of ligands.
In sum, from the in silico results, it is suggested that curcumin
and piperine with good affinities to target sites have met the
two criteria set out in this study, namely, as an inhibitor of
ACh hydrolysis through CAS interaction and, concurrently,
preventing Aβ plaque aggregation through PAS inhibition.
On the other hand, bacoside A and chebulinic acid may not
be suitable drug candidates for AD. Thus, only curcumin
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and piperine were selected for further analyses for its AChE
inhibition activity and biochemical assay via in vitro methods.
For in vitro studies, these two selected plant-based
compounds were tested on their own and in combination
with each other. This co-effect approach that is gaining traction
was employed on the grounds that synergistic effects of
plant combinations exhibit augmented functional properties
compared to the effects of individual plants alone (Pereira et al.,
2014). Encouraging data reported in combined administration
of curcumin and piperine in studies relating to benzo(a)pyrene
toxicity (Sehgal et al., 2012) and diethylnitrosamine-induced
hepatocellular carcinoma (Patial et al., 2015) have provided
further evidence that combination treatment using these two
compounds may provide more pronounced results than on their
own. As such, in recent years, synergy evaluation has become
a key area in phytomedicine research exploring the underlying
scientific principles for their therapeutic advantages of multidrug
combinations over single constituents often observed in
traditional medicine (Wagner and Ulrich-Merzenich, 2009).
For in vitro AChE enzyme screening, donepezil was used as
a positive control and its percentage inhibition values, as well
as its IC50 value, were compared to curcumin and piperine. It
was noted that donepezil inhibited AChE in a dose-dependent
manner and reached its maximal inhibition between 100 and
250 µg/ml. As for the test compounds, the percentage of
inhibition for the combination showed that they were much more
effective than using curcumin and piperine singularly. Although
investigation into the AChE inhibitory potential of these
compounds have been done, no study has tested the compounds
in combination. Since our data of curcumin and piperine,
singularly, are consistent with other published results, the greater
inhibition values obtained in this study, when both compounds
were used in combination, is indeed promising. For reference,
in regard to piperine alone, Kumar et al. (2012) discovered
that piperine had a highly significant inhibitory effect on AChE
in both aqueous and ethanolic extract. Likewise, the study by
Ingkaninan et al. (2003) on Thai traditional and neurotonic
remedial plants also showed that Piper nigrum extracts at
0.1 mg/ml containing piperine had a 50%–65% inhibitory activity
on AChE. As for curcumin alone, Ahmed and Gilani (2009)
found that curcumin showed the least potency when compared to
other curcuminoids present in turmeric. In the case for dementia,
Murata et al. (2015) showed that black pepper and turmeric
extracts were potent compounds in inhibiting AChE, proposing
that both extracts could have preventive and therapeutic
effects on dementia.
As for the combination of curcumin and piperine, we
observed in our data that almost half of the concentration of
piperine was required to give the desired combinatory effects
with curcumin, which again explained the enhancing nature of
piperine (Singh et al., 2015). In light of accumulating evidences
of AChE accelerating Aβ deposition, which indicate that AChE
could play a role in the early stages of senile plaque development
(Inestrosa et al., 1996), the promising results of curcumin and
piperine in in vitro enzyme screening corroborates with our
in silico predictions that the inhibitory interactions with PAS of
AChE may prevent Aβ aggregation. A previous study has shown
that AChE has secondary non-cholinergic functions including
the processing and deposition of Aβ (Castro and Martinez, 2006).
Moreover, AChE co-localizes with Aβ in neuritic plaques and
accelerates the assembly of Aβ into fibrils. In turn, the Aβ peptide
regulates AChE expression, assembly and glycosylation in cell
culture, and transgenic mice and brain of AD patients (Hu et al.,
2003). Thus, inhibition of the Aβ aggregation process within the
AChE is believed to be beneficial in preventing AD progression.
In regard to compound concentrations, combinatory studies
of curcumin and piperine in different in vivo studies show
that piperine, at all doses used in the studies, can enhance the
serum concentration, extent of absorption, and bioavailability
of curcumin up to 2000% in both rats and humans with no
adverse effects (Shoba et al., 1998). Thus, this allays the toxicity
concern even if curcumin and piperine may be needed to be
consumed in larger amounts for its therapeutic effects. In sum,
these findings further substantiate the claims that curcumin
and piperine may be developed as alternative synthetic AChE
inhibitors for preventative purposes in AD.
With the growing burden of AD care and increasingly
younger age of AD patients, we recognize the need of a
compound that has therapeutic roles in addition to preventative
functions. Hence, we extended this study by evaluating the
effect of curcumin and piperine on Aβ toxicity via an
in vitro cell line. To determine whether the compounds can
inhibit Aβ42-induced cytotoxicity, we examined the effect of
Aβ42 added to the cell medium upon dissolution and Aβ42
pre-incubated with all test compounds (donepezil, curcumin,
and piperine used singularly and in combination) in SH-SY5Y
cells (Figure 9). The optimized concentration of combined
curcumin and piperine was selected for subsequent analyses in
this study. We observed that Aβ exerted degeneration effects
toward the cells, as indicated by a drop in cell viability, and
the effect was reversed after treatment with all test compounds.
More significantly, cell viability was enhanced in Aβ-treated
SH-SY5Y cells upon pre-treatment with combined curcumin and
piperine as compared to singular compounds. This suggested
that combined compounds exhibit greater protective effect in
cells when exposed to cytotoxic Aβ. On its own, protecting
neuron cells from Aβ neurotoxicity by treating them with
curcumin have also been shown in other studies. A recent article
focused on the potential effect of curcumin upon Aβ-induced
cytotoxicity in HT-22 cells showed a remarkable increase in
cell viability, following 48 h of treatment with curcumin, when
compared to cells that were treated with Aβ1–42 only (Zhang
et al., 2018). Likewise, another study revealed that curcumin at
lower doses (0.1, 0.5, and 2.5 µM) enhanced the proliferation
of neural stem cells, but at higher doses (12.5 and 62.5 µM),
it reduced neural stem cell proliferation (Xiaoxiao et al., 2015),
which was also concordant with our findings. Neuroprotective
effects of individual curcumin (Yin et al., 2012) and piperine
(Chonpathompikunlert et al., 2011) on cells have also been
reported. While this study is the first in vitro investigation
into combinatory curcumin and piperine, a parallel finding
can be drawn from Chonpathompikunlert et al. (2011) who
reported that piperine coupled with nitroxide radical-containing
nanoparticles (RNPs) can increase the viability of SH-SY5Y cells
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that have been induced with 20 µM Aβ1–42. Their results also
showed that a viability of almost 100% in SH-SY5Y was achieved
when piperine was used in the presence of 1 mM RNP. However,
in the case of piperine used singularly, the viability was decreased
at high piperine concentration region (>1 mM) due to its
cytotoxicity. This finding is consistent with our results whereby
EC of individual piperine was obtained at a lower concentration
of 25 µM (Figure 7).
To account for the significant inhibition by compound on
Aβ42-induced cell toxicity, we carried out further experiments
designed to elucidate the effects of test compounds upon
aggregation process of Aβ42 using ThT fluorescence assay. Our
results showed that all test compounds were able to inhibit
fibrillation of Aβ42 (Figure 10A) as well as to disaggregate the
fibrils (Figure 10B), as displayed in the lower intensity of the
ThT fluorescence. ThT is a well-known marker for protein fibril
formation as the fluorescence increases upon binding to fibril
aggregates composed of beta strands. The toxicity of Aβ peptides
correlates well with their propensity to aggregate. The process of
fibrillogenesis begins with amyloid monomers that assemble to
form dimers and small oligomer species, followed by aggregation
of oligomers to further construct short, irregular protofibrils
and elongate into insoluble fibrils via a complex multistep-
nucleated polymerization (Cheignon et al., 2018). Once Aβ
aggregates extracellularly to form fibrils, it becomes resistant
to proteolytic cleavage (Durell et al., 2018). Our strategy was
to either inhibit or disaggregate the fibril formation process to
prevent amyloidogenesis by using optimized concentrations of
singular and combined compounds.
In the last decade, considerable progress has been made
on using curcumin in AD therapy. Several lines of evidence
suggested that curcumin has anti-amyloid properties in AD.
Findings from an in vivo study revealed that curcumin inhibits
Aβ aggregation as well as disaggregates to form fibrillar
Aβ40 (Yang et al., 2005). A previous study also reported
that curcumin-functionalized gold nanoparticles (Au-curcumin)
of hydrodynamic diameter 10–25 nm was able to inhibit
amyloid fibrillation and disintegrate amyloid fibrils (Palmal
et al., 2014). In their research, they showed that curcumin
was water-soluble when in nanoparticle form, which made it
efficient to interact with amyloid proteins, thus offering an
enhanced ability in inhibiting amyloid fibrillation and dissolving
amyloid fibrils. Furthermore, curcumin and its derivatives
were reported to inhibit the fibrillar Aβ formation from Aβ
monomer and destabilizes preformed fibrillar Aβ in vitro as
well, indicating that curcumin was protective against Aβ toxicity
(Ono et al., 2003), which is consistent with our findings. While
emerging evidence on curcumin against Aβ has been reported,
involvement of piperine in Aβ fibrillation process has yet to
be elucidated. But from our data, piperine might play a role in
disintegrating the Aβ fibril formation. Recent studies reported
that indirect involvement of piperine-coated gold formation
was able to inhibit amyloid-prone residues of insulin (Anand
et al., 2017, 2018). They found that the process of both
spontaneous and seed-induced (misfolded protein aggregates)
amyloid formation of insulin was strongly inhibited in the
presence of piperine-coated gold nanoparticles. Furthermore,
the piperine molecule has a unique structure, which is known
to interact with proteins and DNA molecules through viable
H-bonds mediated via its C = O and –O– functional groups
(Chinta et al., 2015; Yeggoni et al., 2015). Formation of
strong H-bonds between piperine and valine residues of protein
molecules has already been reported (Zsila et al., 2005).
These evidence might suggest the mechanism of piperine
interaction with Aβ, which we would need to further validate
in the future.
Several studies have shown that Aβ can produce oxidative
stress (Kim et al., 2003; Cutler et al., 2004; Chauhan and
Chauhan, 2006). Upon deposition in the brain, Aβ induces
oxidative changes that render nerve cell vulnerable to insults.
Aβ-mediated oxidative stress could be due to either the
increase in ROS production, decrease in enzyme activities
involved in the antioxidant defense system, or dysfunctional
mitochondria (Chauhan and Chauhan, 2006). In order to
evaluate the deleterious effect caused by Aβ and the reverse
effect contributed by natural compounds, we analyzed the
oxidative product and the activity of antioxidant enzymes in
terms of Aβ damage. We observed that our findings were in
agreement with previous findings mentioned above where Aβ
caused substantial toxic effects towards the antioxidant defense
mechanism, as indicated by the significant increase in MDA
level and reduced levels of glutathione and catalase enzymes.
However, upon treatment with all test compounds, a reversal of
the deleterious effects caused by Aβ was noted. More remarkably,
a more pronounced rehabilitation effect was observed for
the combination of curcumin and piperine as compared to
individual compounds.
Cell membrane is made up of phospholipids that are
composed of polyunsaturated fatty acids, which serve as
the prime targets of ROS. The presence of a double bond
adjacent to the methylene group makes the methylene C–H
bond of polyunsaturated fatty acids weaker, and therefore,
the hydrogen becomes more prone to elimination. Production
of free radicals such as hydroxyl radical (•OH), alkoxy
radicals (RO•), and peroxy radicals (ROO•) results in the
initiation of the lipid peroxidation sequence. Several studies
suggested that Aβ enhances oxidative stress by increasing lipid
peroxidation. The Aβ25–35 (Aβ containing hydrophilic and
hydrophobic domains) treatment enhanced lipid peroxidation
as arbitrated by the intensified levels of thiobarbituric-acid-
reactive substances in the brain (Um et al., 2006). These products
of lipid oxidation structurally modify proteins by covalent
interactions and inhibition of enzyme function. Since lipids are
membrane components, the interaction of Aβ aggregates with
membrane results in impairment of cellular processes, causing
oxidative stress and increased free calcium ion concentration that
eventually leads to apoptotic cell death (Kirkitadze and Kowalska,
2005). GPx and catalase are the two main enzymes involved in
cellular protection against damages due to oxygen-derived free
radicals. In other words, these are important scavenging enzymes
that can reduce H2O2 (Flohé and Günzler, 1984; Chelikani et al.,
2004), which suggests a role in AD pathology. Altered glutathione
metabolism in association with increased oxidative stress has
been implicated in the pathogenesis of AD (Reid and Jahoor,
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2001). Decreased GSH in lymphoblasts carrying presenilin and
APP gene mutations indicate the role of presenilin and APP
in oxidative stress in AD (Cecchi et al., 1999). Based on these
literature findings, the role of natural products in preventing
oxidative stress has been extensively studied (Kim et al., 2005;
Calaf et al., 2011; Carocho and Ferreira, 2013; Ali et al., 2018;
Fischer et al., 2018; Simioni et al., 2018).
Our findings are in agreement with other studies on the
antioxidant effect of curcumin against oxidative damages. A
previous study reported that curcumin enhanced the levels of
glutathione, superoxide dismutase, and catalase in the brains of
lead-poisoned rats while it significantly reduced lead-induced
damage (Shukla et al., 2003). Curcumin also protects PC12 cells
and normal human umbilical endothelial cells from Aβ-induced
oxidative stress (Park and Kim, 2002). Moreover, using the
same SY5Y cells as was selected in this study, Ug˘uz et al.
(2016) demonstrated that curcumin can suppress the levels of
lipid peroxidation, glutathione, and caspase that were induced
by peroxides. In addition, according to Calaf et al. (2011),
curcumin is a good scavenger of H2O2 at high concentrations
(over 27 µM) and inhibition of peroxidation by curcuminoids
is primarily attributed to the scavenging of the reactive free
radicals involved in such a process. As for piperine, it has also
been used against oxidative stress in that it plays a crucial
role in reducing chemical carcinogen-induced oxidative stress
(Khajuria et al., 1998). Piperine enhances the action of phase
II detoxification enzyme and reduces the level of DNA damage
and DNA–protein cross-links (Selvendiran et al., 2005). A recent
study by Verma et al. (2018) using various biomarkers such as
comet and lipid peroxidation revealed that piperine at 35 and
50 mM concentrations can significantly reduce the tail moment
and peroxidation of lipids induced by cadmium (Cd), which
further acknowledges the protective effects of piperine. Hence, it
can be concluded that curcumin and piperine have potentiated
these scavenging enzymes with different pathways to decrease
oxidative stress, thereby possibly serving as a therapeutic tool
for AD.
CONCLUSION
Curcumin, piperine, bacoside A, and chebulinic acid are plant-
based compounds with long-rooted beliefs of cognitive benefits
that have been extensively used in food and traditional medicine.
This study investigated the potential of these compounds as
preventative and therapeutic drugs for AD. Divided into two
parts, the in silico section has narrowed down the compounds
to only curcumin and piperine, based on their favorable binding
affinities to AChE and simultaneous interactions with key amino
acids of CAS and PAS. On the other hand, bacoside A and
chebulinic acid may not be suitable drug candidates owing to
their inabilities to adopt favorable conformations within the
narrow AChE gorge binding sites.
The second part of this study through in vitro methods
have demonstrated that curcumin combined with piperine is
able to protect SH-SY5Y cells against Aβ-induced cytotoxicity,
fibrillation, and oxidative damage by attenuating the toxic
effects on neuron cells, inhibiting and disaggregating the fibrils
as well as suppressing the generation of ROS. To date, this
article is the only study that focuses on the combinatory
effect of curcumin and piperine for AD treatment. Although
many studies have been conducted on these two compounds,
none has adopted the synergistic approach by using individual
compound effects as the baseline comparison. We believe
that the consistency of our results for individual compounds
with other publications substantiates the methodology used
for our combinatory studies. In addition, the strength of this
study is supported by the corroboration of results between
in silico prediction and in vitro testing on AChE inhibition.
On the whole, this report reinforces the benefits of co-effects
from different compounds in treating challenging diseases
such as AD.
The effects might also involve amyloidogenic and antioxidant
properties in different pathways of curcumin and piperine, as
well as interactions between complex AChE and Aβ, which
requires further investigation. Furthermore, synergistic behavior
indicates that the combination of these two compounds at
lower concentration may provide a better outcome rather than
treatment with singular compounds. Further experiments at a
molecular level and animal studies are currently underway.
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